Trintellix (vortioxetine): The 2026 Generic Opportunity Window

Trintellix, H. Lundbeck and Takeda's multimodal oral antidepressant (vortioxetine hydrobromide), generates over $1.3 billion in annual global sales, with the U.S. market accounting for approximately $1.0 billion in annual net revenue. No generic vortioxetine is commercially sold in the United States today, maintaining a 100% brand-only market. Primary composition-of-matter patent US 7,144,884 ('1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a serotonin reuptake inhibitor and 5-HT3 antagonist') expires on December 17, 2026, inclusive of a six-month pediatric exclusivity extension granted under Section 505A of the FD&C Act. In December 2023, the Federal Circuit affirmed in H. Lundbeck A/S v. Lupin Ltd. that generic ANDA applicants using skinny labels carve out method-of-use claims without inducing infringement. Leading Indian generic manufacturers including Lupin Limited, Zydus Lifesciences, Alembic Pharmaceuticals, and Macleods Pharmaceuticals hold active Paragraph IV ANDAs poised to enter this multi-billion dollar market upon the December 17, 2026 patent transition.